Eberechukwu Onukwugha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1699629/publications.pdf

Version: 2024-02-01

111 1,805 21 37 g-index

111 111 111 111 3349

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 683-690.	0.7	8
2	Discharges against medical advice and 30-day healthcare costs: an analysis of commercially insured adults. Journal of Comparative Effectiveness Research, 2022, 11, 169-177.	0.6	2
3	The economic burden of Parkinson disease among Medicare beneficiaries. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 405-414.	0.5	4
4	Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 1013-1020.	0.7	1
5	Cost–effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer. Journal of Comparative Effectiveness Research, 2022, 11, 595-607.	0.6	1
6	Exploring the Use of State Medical Cannabis Legislation as a Proxy for Medical Cannabis Use Among Patients Receiving Chemotherapy. Current Treatment Options in Oncology, 2021, 22, 1.	1.3	5
7	Voice Interface Technology Adoption by Patients With Heart Failure: Pilot Comparison Study. JMIR MHealth and UHealth, 2021, 9, e24646.	1.8	21
8	Early Stage Investigators: Emerging Research Supporting Health Equity. Ethnicity and Disease, 2021, 31, 165-166.	1.0	0
9	Health Care Resource Utilization Associated With Parkinson Disease Among Medicare Beneficiaries. Neurology, 2021, 97, e597-e607.	1.5	7
10	Why the Gap in Evaluating the Social Constructs and the Value of Medicines?. Pharmacoeconomics, 2021, 39, 1365-1372.	1.7	3
11	Valuing diversity in value assessment: introducing the PhRMA Foundation Health Disparities Challenge Award. Journal of Managed Care & Decialty Pharmacy, 2021, 27, C2-C3.	0.5	O
12	The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities. Journal of Managed Care & Decialty Pharmacy, 2021, 27, S2-S11.	0.5	2
13	Utilization of Screening Mammograms in the Medicare Population Before and After the Affordable Care Act Implementation. Journal of Aging and Health, 2020, 32, 25-32.	0.9	2
14	The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation. Pharmacoeconomics, 2020, 38, 109-119.	1.7	1
15	Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data. Leukemia and Lymphoma, 2020, 61, 75-83.	0.6	3
16	Patient-level Factors Associated With the Initial Management of Older Adults Diagnosed With Follicular Lymphoma: A Surveillance, Epidemiology, and End Results–Medicare Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e184-e194.	0.2	4
17	Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. Pharmacoeconomics, 2020, 38, 233-242.	1.7	19
18	Survival benefit associated with treating follicular lymphoma in patients 80 years or older. Journal of Geriatric Oncology, 2020, 11, 55-61.	0.5	2

#	Article	lF	Citations
19	Utilization of novel systemic therapies for multiple myeloma: A retrospective study of frontâ€line regimens using the SEERâ€Medicare data. Cancer Medicine, 2020, 9, 626-639.	1.3	8
20	Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients. Future Oncology, 2020, 16, 353-365.	1.1	5
21	The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1353-1362.	0.5	2
22	Initiation of Transdermal Fentanyl Among US Commercially Insured Patients Between 2007 and 2015. Pain Medicine, 2020, 21, 2229-2236.	0.9	2
23	The bird's-eye view: A data-driven approach to understanding patient journeys from claims data. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1037-1045.	2.2	7
24	Continuity of Care and Mental Health Service Use Among Medicaid-enrolled Youths. Medical Care, 2020, 58, 199-207.	1.1	8
25	Cost-Related Non-Utilization of Health Services and Self-Perceived Reactions to Race. Ethnicity and Disease, 2020, 30, 399-410.	1.0	2
26	Early Stage Investigators: Emerging Research Supporting Health Equity. Ethnicity and Disease, 2020, 30, 517-518.	1.0	0
27	Chronic non-cancer pain and its association with healthcare use and costs among individuals with obstructive sleep apnea. Pain Management, 2020, 10, 377-386.	0.7	3
28	Healthcare Resource Utilization Following a Discharge Against Medical Advice: An Analysis of Commercially Insured Adults. Journal of Hospital Medicine, 2020, 15, 716-722.	0.7	1
29	Prescription drug monitoring programs: Assessing the association between "best practices―and opioid use in Medicare. Health Services Research, 2019, 54, 1045-1054.	1.0	9
30	Case Articleâ€"Baseball Analytics: Advancing to Prescriptive Analytics in the Major League Baseball Front Office. INFORMS Transactions on Education, 2019, 19, 143-145.	0.4	3
31	Case—Baseball Analytics: Advancing to Prescriptive Analytics in the Major League Baseball Front Office. INFORMS Transactions on Education, 2019, 19, 146-151.	0.4	1
32	Epidemiological Determinants of Advanced Prostate Cancer in Elderly Men in the United States. Clinical Medicine Insights: Oncology, 2019, 13, 117955491985511.	0.6	5
33	Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis. Rheumatology and Therapy, 2019, 6, 611-616.	1.1	11
34	An ecological approach to monitor geographic disparities in cancer outcomes. PLoS ONE, 2019, 14, e0218712.	1.1	7
35	Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population. Infectious Diseases and Therapy, 2019, 8, 219-228.	1.8	9
36	Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 260-271.	0.5	8

#	Article	IF	CITATIONS
37	On a Firm's Optimal Response to Pressure for Gender Pay Equity. Organization Science, 2019, 30, 214-231.	3.0	25
38	Against Medical Advice Discharges Are Increasing for Targeted Conditions of the Medicare Hospital Readmissions Reduction Program. Journal of General Internal Medicine, 2019, 34, 515-517.	1.3	14
39	PEER-REVIEWED JOURNAL EDITORS' VIEWS ON REAL-WORLD EVIDENCE. International Journal of Technology Assessment in Health Care, 2018, 34, 111-119.	0.2	11
40	Impact of United States Preventive Services Task Force Recommendations on Utilization of Prostate-specific Antigen Screening in Medicare Beneficiaries. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1069-1075.	0.6	5
41	Stated Pain Levels, Opioid Prescription Volume, and Chronic Opioid Use Among United States Army Soldiers. Military Medicine, 2018, 183, e322-e329.	0.4	3
42	Sensitivity of the Medication Possession Ratio to Modelling Decisions in Large Claims Databases. Pharmacoeconomics, 2018, 36, 369-380.	1.7	14
43	Impact of Coordinated Behavioral Health Management on Quality Measures of Antipsychotic Use. Administration and Policy in Mental Health and Mental Health Services Research, 2018, 45, 174-185.	1.2	7
44	An Approach to Identify Delivery of Palliative Radiation Therapy Using Health Care Claims Data: A Proof-of-Concept Application of a Visual Analytics Tool. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	1.0	0
45	Impact of a Care Management Entity on Use of Psychiatric Services Among Youths With Severe Mental or Behavioral Disorders. Psychiatric Services, 2018, 69, 1167-1174.	1.1	4
46	Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 340.e23-340.e31.	0.8	0
47	Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer. PLoS ONE, 2018, 13, e0193661.	1.1	8
48	Examining patient–provider relationship (PPR) quality and patient activation in the Medicare population. Aging Clinical and Experimental Research, 2017, 29, 543-548.	1.4	16
49	Specialist visits and initiation of cancer-directed treatment among a large cohort of men diagnosed with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 150.e17-150.e23.	0.8	3
50	Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10ÂUS States. Addiction, 2017, 112, 1784-1796.	1.7	91
51	The Impact of Coverage Restrictions on Antipsychotic Utilization Among Low-Income Medicare Part D Enrollees. Administration and Policy in Mental Health and Mental Health Services Research, 2017, 44, 943-954.	1.2	1
52	Nonmedical Out-of-Pocket Patient and Companion Expenditures Associated With Glaucoma Care. Journal of Glaucoma, 2017, 26, 343-348.	0.8	4
53	Adherence to Antipsychotic Therapy: Association With Hospitalization and Medicare Spending Among Part D Enrollees With Schizophrenia. Psychiatric Services, 2017, 68, 1185-1188.	1.1	11
54	Redaction of Substance Abuse Claims in Medicare Research Files Affects Spending Outcomes for Nearly One in Five Beneficiaries with Serious Mental Illness. Health Services Research, 2017, 52, 1239-1248.	1.0	6

#	Article	IF	CITATIONS
55	Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone. PLoS ONE, 2017, 12, e0175956.	1.1	4
56	Foreword: Big Data and its Application in Health Disparities Research. Ethnicity and Disease, 2017, 27, 69.	1.0	6
57	Against Medical Advice Discharges. Journal of Hospital Medicine, 2017, 12, 843-845.	0.7	23
58	Sequential Therapies and the Cost-Effectiveness of Treating Metastatic Colon Cancer Patients. Journal of Managed Care & Decialty Pharmacy, 2016, 22, 628-639.	0.5	5
59	Data Visualization Tools for Investigating Health Services Utilization Among Cancer Patients. , 2016, , 207-229.		3
60	Research is needed on the difficultâ€ŧoâ€cure population of hepatitis C virus patients with disability. Hepatology, 2016, 63, 2067-2068.	3.6	0
61	Great expectations: An analysis of major league baseball free agent performance. Statistical Analysis and Data Mining, 2016, 9, 295-309.	1.4	8
62	Strategies to Prevent MRSA Transmission in Community-Based Nursing Homes: A Cost Analysis. Infection Control and Hospital Epidemiology, 2016, 37, 962-966.	1.0	5
63	Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis. Pharmacoeconomics, 2016, 34, 91-93.	1.7	20
64	Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?. Pharmacoeconomics, 2016, 34, 1067-1070.	1.7	5
65	Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. Oncologist, 2016, 21, 676-683.	1.9	7
66	Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis. Cancer Medicine, 2016, 5, 3300-3309.	1.3	23
67	Understanding Adherence and Prescription Patterns Using Large-Scale Claims Data. Pharmacoeconomics, 2016, 34, 169-179.	1.7	18
68	Large exposure estimation through automatic business group identification. Annals of Operations Research, 2016, 247, 503-521.	2.6	3
69	Cost Prediction Using a Survival Grouping Algorithm: An Application to Incident Prostate Cancer Cases. Pharmacoeconomics, 2016, 34, 207-216.	1.7	7
70	Cost-of-Illness Studies: An Updated Review of Current Methods. Pharmacoeconomics, 2016, 34, 43-58.	1.7	74
71	ReCAP: Impact of Multidisciplinary Care on Processes of Cancer Care: A Multi-Institutional Study. Journal of Oncology Practice, 2016, 12, 155-156.	2.5	24
72	Determinants of Receipt of Stem Cell Transplant in Elderly Medicare Beneficiaries with Multiple Myeloma. Blood, 2016, 128, 5927-5927.	0.6	0

#	Article	IF	CITATIONS
73	Patterns and Determinants of Cancer-Directed Drug Therapy in Medicare Beneficiaries with Multiple Myeloma. Blood, 2016, 128, 5926-5926.	0.6	O
74	Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare. Medical Care, 2015, 53, e58-e64.	1.1	32
7 5	Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods. BMC Medical Research Methodology, 2015, 15, 65.	1.4	23
76	Racial variation in the clinical and economic burden of skeletal-related events among elderly men with stage IV metastatic prostate cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 471-485.	0.7	3
77	A Primer on Marginal Effectsâ€"Part I: Theory and Formulae. Pharmacoeconomics, 2015, 33, 25-30.	1.7	36
78	Racial disparities in urologist visits among elderly men with prostate cancer: A cohort analysis of patientâ€related and county of residenceâ€related factors. Cancer, 2014, 120, 3385-3392.	2.0	13
79	Does the type of firstâ€line regimens influence the receipt of secondâ€line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Medicine, 2014, 3, 124-133.	1.3	5
80	Cardiovascular eventâ€free survival after adjuvant radiation therapy in breast cancer patients stratified by cardiovascular risk. Cancer Medicine, 2014, 3, 1342-1352.	1.3	23
81	Discriminatory power of a 25-item distress screening tool: a cross-sectional survey of 251 cancer survivors. Quality of Life Research, 2014, 23, 2855-2863.	1.5	10
82	Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer. BMC Medical Research Methodology, 2014, 14, 1.	1.4	403
83	Hospital Center Effect for Laparoscopic Colectomy Among Elderly Stage I-III Colon Cancer Patients. Annals of Surgery, 2014, 259, 924-929.	2.1	16
84	Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Current Opinion in Oncology, 2014, 26, 274-283.	1.1	39
85	Skeletal-related events and mortality among older men with advanced prostate cancer. Journal of Geriatric Oncology, 2014, 5, 281-289.	0.5	24
86	The use of health services among elderly patients with stage IV prostate cancer in the initial period following diagnosis. Journal of Geriatric Oncology, 2014, 5, 290-298.	0.5	8
87	The probabilistic reduction approach to specifying multinomial logistic regression models in health outcomes research. Journal of Applied Statistics, 2014, 41, 2206-2221.	0.6	1
88	Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients. Advances in Therapy, 2014, 31, 724-734.	1.3	6
89	Improving Confidence in Observational Studies. Pharmacoeconomics, 2013, 31, 177-179.	1.7	2
90	Engaging hard-to-reach patients in patient-centered outcomes research. Journal of Comparative Effectiveness Research, 2013, 2, 313-324.	0.6	47

#	Article	IF	CITATIONS
91	The emerging relevance of heterogeneity of treatment effect in clinical care: a study using stage IV prostate cancer as a model. Journal of Comparative Effectiveness Research, 2013, 2, 605-618.	0.6	2
92	Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. Cancer Medicine, 2013, 2, 907-915.	1.3	6
93	A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting: Figure 1. BMJ Open, 2012, 2, e000902.	0.8	17
94	A Sustainable Strategy to Prevent Misuse of Antibiotics for Acute Respiratory Infections. PLoS ONE, 2012, 7, e51147.	1.1	37
95	Comparative and costâ€effectiveness of oxaliplatinâ€based or irinotecanâ€based regimens compared with 5â€fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients. Cancer, 2012, 118, 3173-3181.	2.0	12
96	Sensitivity Analysis in Cost-Effectiveness Studies. Pharmacoeconomics, 2011, 29, 297-314.	1.7	63
97	Effect of Urologists and Medical Oncologists on Treatment of Elderly Men With Stage IV Prostate Cancer. Urology, 2011, 77, 1088-1095.	0.5	9
98	Readmissions After Unauthorized Discharges in the Cardiovascular Setting. Medical Care, 2011, 49, 215-224.	1.1	11
99	Chemotherapy Treatment and Survival in Older Women with Estrogen Receptor–Negative Metastatic Breast Cancer: A Populationâ€Based Analysis. Journal of the American Geriatrics Society, 2011, 59, 637-646.	1.3	21
100	Racial Variation in the Cost-Effectiveness of Chemotherapy for Prostate Cancer. Journal of Oncology Practice, 2011, 7, e16s-e24s.	2.5	8
101	Reasons for discharges against medical advice: a qualitative study. BMJ Quality and Safety, 2010, 19, 420-424.	1.8	34
102	Bernoulli Regression Models: Revisiting the Specification of Statistical Models with Binary Dependent Variables. Journal of Choice Modelling, 2010, 3, 1-28.	1.2	31
103	Health Disparities in Staging of SEER-Medicare Prostate Cancer Patients in the United States. Urology, 2010, 76, 566-572.	0.5	22
104	Healthcare Rationing by Proxy. Pharmacoeconomics, 2010, 28, 175-184.	1.7	64
105	Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. American Journal of Managed Care, 2010, 16, 447-56.	0.8	13
106	The dual impact of rehabilitation admission and race/ethnicity on discharges against medical advice. NeuroRehabilitation, 2009, 24, 67-74.	0.5	5
107	The total economic burden of overactive bladder in the United States: a disease-specific approach. American Journal of Managed Care, 2009, 15, S90-7.	0.8	77
108	Ethnic disparities, hospital quality, and discharges against medical advice among patients with cardiovascular disease. Ethnicity and Disease, 2009, 19, 172-8.	1.0	13

#	Article	IF	CITATIONS
109	Effects of a Medicaid prior authorization policy for pregabalin. American Journal of Managed Care, 2009, 15, e95-102.	0.8	12
110	Using Cost-Effectiveness Analysis to Sharpen Formulary Decision-Making: The Example of Tiotropium at the Veterans Affairs Health Care System. Value in Health, 2008, 11 , 980-988.	0.1	10
111	Racial Differences in Hospital Discharge Disposition among Stroke Patients in Maryland. Medical Decision Making, 2007, 27, 233-242.	1.2	13